Financial Performance Highlights (Consolidated)

Revenue & Profitability:

  • Revenue from Operations: ₹211.63 crore in H1 FY27, representing 29.78% YoY growth from ₹163.39 crore in H1 FY26
  • EBITDA: ₹23.16 crore in H1 FY27, up 41.54% YoY from ₹16.36 crore in H1 FY26
  • EBITDA Margin: 10.95% in H1 FY27, expanded by 93 basis points from 10.02% in H1 FY26
  • PAT: ₹11.55 crore in H1 FY27, increased 38% YoY from ₹8.37 crore in H1 FY26
  • PAT Margin: 5.46% in H1 FY27 compared to 5.13% in H1 FY26
  • EPS: ₹4.93 in H1 FY27 compared to ₹4.71 in H1 FY26

Comparative Performance:

  • H1 FY27 vs H1 FY26: Revenue growth 29.52%, PAT growth 38.00%
  • H1 FY27 vs H2 FY26: Revenue growth 27.57%, PAT growth 41.62%

Balance Sheet Position (Consolidated as of September 2026)

Assets:

  • Total Assets: ₹375.84 crore
  • Non-Current Assets: ₹50.66 crore (Property, Plant and Equipment: ₹29.99 crore, Capital Work in Progress: ₹3.31 crore, Intangible Assets: ₹12.97 crore)
  • Current Assets: ₹325.18 crore (Inventories: ₹154.46 crore, Trade Receivables: ₹90.92 crore, Cash and Bank Balances: ₹63.33 crore)

Liabilities:

  • Shareholder's Funds: ₹133.47 crore (Share Capital: ₹23.41 crore, Reserves and Surplus: ₹110.07 crore)
  • Non-Current Liabilities: ₹8.55 crore
  • Current Liabilities: ₹233.81 crore (Short Term Borrowings: ₹111.69 crore, Trade Payables: ₹95.87 crore)

Business Operations Update

Product Portfolio:

  • Comprehensive portfolio including herbicides, insecticides, fungicides, plant growth regulators (PGRs), biopesticides and bio-fertilisers
  • 45+ products with continuous additions through regulatory & R&D capabilities
  • Key active ingredients: Acetamiprid, Buprofezin, Emamectin benzoate, Imidacloprid, Paraquat Dichloride, Pretilachlor, Bispyribac Sodium, Glufosinate Ammonium

Manufacturing & Expansion Plans:

  • Dahej, Gujarat facility commissioned in 2021
  • Current capacities: Solid Formulation - 1,040 MT p.a., Liquid Formulation - 13 lakh litres p.a.
  • Planned expansion: ₹3.75 crore investment to increase Solid Formulation to 2,000 MT p.a. and Liquid Formulation to 50 lakh litres p.a. (Target completion: March 2027)
  • Backward integration: ₹30 crore investment for 250 MTPA technical manufacturing facility (Target commissioning: 2028)

Geographical Presence:

  • Domestic: 400+ dealers across 10 Indian states
  • International: Export to Dominican Republic, Turkey, Egypt, UAE, Ethiopia, Jordan through UAE subsidiary

R&D Capabilities:

  • Focus on formulation innovation, process optimization, and cost reduction
  • Laboratory equipment includes Dyno Mill, Fluidized Bed Dryer, Vertical Extruder, Air Jet Mill, Reaction Vessels

Strategic Priorities

  • Portfolio scale-up with focus on safer chemical formulations and bio-pesticides
  • Export growth leveraging existing international registrations
  • Vertical integration through technical manufacturing capabilities
  • Margin improvement through operating efficiencies and product mix improvement

Management Commentary

Chairman Krishnamurthy Ganesan highlighted positive evolution in business mix with increasing contribution from formulation and branded products, supporting greater value addition and portfolio diversification. Export sales, alongside technical, formulation and branded sales, are identified as key growth drivers.

Key Historical Performance

FY26 Audited Results: Revenue ₹329.29 crore, EBITDA ₹34.26 crore, PAT ₹16.52 crore

FY25 Audited Results: Revenue ₹247.60 crore, EBITDA ₹26.40 crore, PAT ₹12.47 crore

Key Ratios

Debt to Equity: 0.88 (Sep 2026), Current Ratio: 1.39 (Sep 2026), Return on Net Worth: 8.65% (Sep 2026)